secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001193125-25-286419
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA provides pro forma statements for Kineta merger, closed June 30, 2025
----------------------------------------------------------------------------

- Pro forma combined statements for nine months ended Sept 30, 2025 and year ended Dec 31, 2024.
- Kineta acquisition accounted for as business combination; TuHURA as acquirer with 92.4% ownership post-merger.
- Pro forma adjustments eliminate pre-merger intercompany transactions and financing costs.
- TuHURA advancing Kineta's VISTA-101 trial; REM-001 study underway with CVR milestone by Dec 31, 2025.
- Historical financials of TuHURA remain the consolidated financial statements post-merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000119312525286419/0001193125-25-286419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000119312525286419/d851083d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-286419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer